The DOI matches its Crossref record.
Lipid and Apolipoprotein Profiles of Uremic Dyslipoproteinemia -Relation to Renal Function and Dialysis
Abstract
To study the effect of renal function on the development of lipid and apolipoprotein abnormalities in human renal disease, we have investigated 75 patients at different stages of renal insufficiency. The patient population consisted of 19 patients with less advanced renal failure (CRF:1) characterized by a mean glomerular filtration rate (GFR) of 37.4 +/- 14 ml/min, 31 patients with advanced renal failure (CRF:2) having a mean GFR value of 7.9 +/- 7.3 ml/min and 25 patients on maintenance hemodialysis (CRF:HD). Patients in the CRF:1 group had normal plasma triglyceride (TG) and total cholesterol (TC) levels. In the CRF:2 and CRF:HD group, TG levels were increased two- to threefold, together with a moderate elevation of TC levels. All patient groups had elevated levels of VLDL cholesterol and slightly decreased levels of HDL cholesterol. The apolipoprotein profile of all patient groups was characterized by significantly reduced levels of apolipoprotein (Apo)A-I and ApoA-II and significantly increased levels of ApoC-III. CRF:2 and CRF:HD patients had also moderately elevated levels of ApoB, ApoC-I and ApoC-II. Levels of ApoE were only elevated in CRF:HD patients. All patients, regardless of TG levels, had significantly lower ApoA-I/ApoC-III ratios than controls. GFR was positively correlated with ApoA-I and inversely correlated with TC, TG and ApoC-III. CRF:HD patients had slightly higher ApoA-I and ApoA-II and lower ApoB levels compared to CRF:2 patients. Patients with vascular disease had higher TC, TG, ApoB, ApoC-II and ApoE than patients without vascular disease. These results demonstrate that the dyslipoproteinemia with CRF is already manifested at the early stages of disease through its abnormal apolipoprotein rather than lipid profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
Lipoprotein Metabolism and Renal Failure
Attman, P.-O., Samuelsson, O., & Alaupovic, P. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80030-8 · Cited by 355
Self-citationLipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354
Atherosclerosis and arteriosclerosis in chronic renal failure
London, G. M., & Drüeke, T. B. (1997) · Kidney International · doi:10.1038/ki.1997.233 · Cited by 354
Borba, E., & Bonfá, E. (1997) · Lupus · doi:10.1177/096120339700600610 · Cited by 289
Metadata
- Authors
- Attman, P.-O., & Alaupovic, P.
- Venue
- Nephron
- Publisher
- S. Karger AG
- Published
- 1991
- Volume
- 57
- Issue
- 4
- Pages
- 401-410
- ISSN
- 1660-8151 (ISSN-L)
- 2235-3186
- OpenAlex
- W2005238318
- Cited by
- 179
- References
- 0
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid and Apolipoprotein Profiles of Uremic Dyslipoproteinemia -Relation to Renal Function and Dialysis. https://app.cochat.ai/papers/10.1159/000186303
- The paper
- Attman, P.-O., & Alaupovic, P. (1991). Lipid and Apolipoprotein Profiles of Uremic Dyslipoproteinemia -Relation to Renal Function and Dialysis. Nephron. https://doi.org/10.1159/000186303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.